Literature DB >> 10356611

[Palliative radiation oncologic therapy: is patient's age a determining factor of feasibility? A 1-year analysis (1997) at a radiotherapy clinic of an academic teaching hospital].

R Souchon1.   

Abstract

BACKGROUND: Radiotherapy is a successfully proven, feasible and appropriate antineoplastic treatment for the palliation of tumor symptoms. Clinicians sometimes use the argument of the burden of advanced age and limited tolerance to withhold this modality of treatment from older patients. PATIENTS AND METHODS: All cancer patients (n = 827) who presented for the first time to the Department of Radiation Oncology during 1997 were used as a base to analyze if age was a factor with regard to the feasibility and the effectiveness of palliative radiation treatment in patients with measurable tumor burden. The following treatment end-points were analyzed in 440 (53%) patients who were treated palliatively: reduction or management of pain; neurological impairment; superior vena cava syndrome; dysphagia; dyspnea; bleeding or ulceration of the tumor or metastasis as well as prevention from clinically but not yet symptomatic tumor progression, while controlling for age (< 70 years: n = 293, 70 to 75 years: n = 79, > 75 years: n = 68); treatment status (in- or out-patient), range of treatment modalities (radiation and/or chemotherapy, no cancer specific treatment). The frequency of not reaching these treatment goals is a criterium of treatment feasibility and a measure of the effect of the variables.
RESULTS: When comparing primarily palliative and non-palliative treated patients, there were similar frequencies in the defined age groups, which points to the effect of other mechanisms of selection, e.g. effect of comorbidity. In an analysis of the relevant reasons for the discontinuation of treatment in palliatively treated patients (reduction of general condition: n = 31 [7%], comorbidity: n = 1 [0%], treatment toxicity: n = 3 [1%], tumor progression: n = 15 [3%], therapy associated death: n = 11 [3%], at patients own request: n = 8 [2%]) age was not a discernible factor. Frequencies of discontinuation of treatment according to age of patients and treatment status defined as in- vs out-patient are relatively small (< 70 years: 5/85 vs 42/208; 70 to 75 years: 2/29 vs 11/50; > 75 years: 4/29 vs 13/39). There are similarities in the lower age groups and these seem to be independent from the treatment modalities used in each of the age groups.
CONCLUSIONS: This presents an example of how one can analyze and present the treatment results of radiotherapy as part of quality management in a department of radiation oncology. The results confirm that it is not justified to withhold radiation therapy based on advanced age alone.

Entities:  

Mesh:

Year:  1999        PMID: 10356611     DOI: 10.1007/BF02742399

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  6 in total

1.  New study suggests radiation often underused for palliation.

Authors:  A A Skolnick
Journal:  JAMA       Date:  1998-02-04       Impact factor: 56.272

2.  [The importance of a quality standard and performance numbers in radio-oncology].

Authors:  H B Makoski
Journal:  Strahlenther Onkol       Date:  1996-03       Impact factor: 3.621

3.  Is curative radiation therapy in elderly patients limited by increased normal tissue toxicity?

Authors:  M Baumann
Journal:  Radiother Oncol       Date:  1998-03       Impact factor: 6.280

4.  Age has no impact on acute and late toxicity of curative thoracic radiotherapy.

Authors:  T Pignon; A Gregor; C Schaake Koning; A Roussel; M Van Glabbeke; P Scalliet
Journal:  Radiother Oncol       Date:  1998-03       Impact factor: 6.280

5.  Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions.

Authors:  L Repetto; A Venturino; M Vercelli; W Gianni; V Biancardi; C Casella; C Granetto; S Parodi; R Rosso; V Marigliano
Journal:  Cancer       Date:  1998-02-15       Impact factor: 6.860

Review 6.  Cancer in older persons. Magnitude of the problem--how do we apply what we know?

Authors:  R Yancik; L A Ries
Journal:  Cancer       Date:  1994-10-01       Impact factor: 6.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.